Incretin-pathway research comparison · research use
Retatrutide vs tirzepatide vs semaglutide, by receptor target.
The three names get searched together because they sit on one continuum: single, dual, and triple incretin agonism. Semaglutide hits GLP-1 alone, tirzepatide adds GIP, and retatrutide adds glucagon on top. This is a research-framing comparison of how the targets differ — formats, documentation, and where each sits in the literature — not a human-use guide. Titan stocks research-grade retatrutide.
Semaglutide — single GLP-1 agonism
Semaglutide is a single-target GLP-1 receptor agonist and the most heavily published of the three in incretin-pathway research. As a research compound it is the reference point the dual and triple agonists are measured against in the literature.
Tirzepatide — dual GLP-1 / GIP
Tirzepatide adds GIP-receptor activity to GLP-1 agonism, making it a dual incretin agonist. Comparative research literature studies how the second receptor target changes the pharmacology relative to single-agonist GLP-1 analogs.
Retatrutide — triple GLP-1 / GIP / glucagon
Retatrutide is a triple-incretin agonist active at GLP-1, GIP, and glucagon receptors, appearing in published phase-II/III clinical literature on incretin-pathway pharmacology. It is the only one of the three Titan stocks as a research compound (10mg lyophilized).
Side by side
The comparison researchers actually search for.
| Attribute | Semaglutide | Tirzepatide | Retatrutide |
|---|---|---|---|
| Receptor target | GLP-1 agonist (single) | GLP-1 + GIP agonist (dual) | GLP-1 + GIP + glucagon (triple) |
| Compound class | Incretin mimetic | Dual incretin agonist | Triple incretin agonist |
| Research literature | Most-studied incretin analog | Dual-agonist phase III literature | Triple-agonist phase II/III literature |
| Common research format | Lyophilized vial | Lyophilized vial | Lyophilized vial |
| Reconstitution | Bacteriostatic water | Bacteriostatic water | Bacteriostatic water |
| Titan catalog | Not stocked | Not stocked | Retatrutide 10mg lyophilized |
Receptor-target comparison for research framing only. No human-use, dosing, safety, or efficacy claim is made or implied.
Order research-grade retatrutide.
Titan stocks retatrutide (10mg lyophilized) with a lot-matched release sheet, an HPLC ≥99% main-peak purity target, and crypto checkout. Open the product page for current pricing and documentation.
Compare research compounds
Other peptide comparisons researchers run before sourcing.
Each Titan comparison breaks down the structural differences, research format, and documentation a buyer should confirm — lot-matched COA, HPLC purity target, and a clear research-use boundary. Pick the pair you're evaluating.
GLP-1 / metabolic research
Growth-hormone secretagogue research
Recovery & repair research
Neuropeptide & nasal-format research